News & Comments- Prohost Biotech - Exclusive Biotech Research

Category: News & Comments

Reata Pharmaceuticals’ Product Omaveloxolone Met the Trial Primary Endpoints in Treating Friedreich’s Ataxia

Reata Pharmaceuticals Omaveloxolone for Friedreich's Ataxia On October 14, 2019 Reata Pharmaceuticals ( RETA ) announced the Part 2 portion of its Phase 2 MOXIe trial, with its product omaveloxolone, met its primary endpoint in modifying Friedreich’s ataxia ( FA...

October 16, 2019

The FDA granted Paratek two important product approvals. One is for acne

The U.S. Food and Drug Administration (FDA) has approved Paratek Pharmaceuticals' (PRTK) product Seysara™ (sarecycline) for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Paratek has exclusively licensed U.S. development and commercialization rights...

October 3, 2018

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

Exelixis (EXEL) announced its initiation of a phase 3 pivotal trial (COSMIC-311) of Cabometyx (cabozantinib) in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies . The co-primary endpoints for...

October 9, 2018

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

Spring Bank Pharmaceuticals, Gilead Sciences and HBV If Spring Bank Pharmaceuticals' ( SBPH ) product inarigivir in combination with Gilead Sciences' ( GILD ) Vemlidy® could validate the current encouraging results of the ongoing trials on chronic hepatitis B virus...

October 24, 2019

Its All About Coronavirus

Coronavirus: The Possible Treatments While Moderna’s ( MRNA ) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human...

March 19, 2020

Amgen's product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

Amgen (AMGN) announced that Amgevita TM , a biosimilar to adalimumab , will launch in markets across Europe beginning on October 16, 2018 . According to Amgen’s press release, Amgevita TM is the first adalimumab biosimilar to be approved by the European Commission ...

October 16, 2018

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

Regenxbio Misleading Selloff A selloff of Regenxbio ( RGNX ) stock, following the FDA’s partial hold on the intrathecal administration of AVXS-101, is unwarranted and totally misleading. Why? Because the selloff of RGNX gave the impression that the gene...

October 31, 2019

The FDA Approves Compugen's IND for Its Oncology Product COM902

Compugen FDA Approval for COM902 Compugen Announces FDA Clearance of IND Application for COM902 Phase 1 clinical study in patients with advanced malignancies expected to begin in early 2020 Clinical development of COM902 will enable testing the combination treatment with...

November 4, 2019

The Bad News That Might Save the Life of Halozyme Therapeutics

Halozyme Therapeutics is Focusing on ENHANZE® Technology Halozyme Therapeutics ( HALO ) decides to focus on its ENHANZE® drug delivery technology, halt the development activities for PEGPH20 and close its oncology operations. These decisions were made after the failure of ...

November 6, 2019

Alleviating osteoarthritis pain without the need for opioid drugs

Tanezumab , an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all three co-primary endpoints in patients with osteoarthritis (OA) . The 16-week Phase 3 study, which evaluated subcutaneous administration of tanezumab in patients with...

October 25, 2018

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024